Insight Molecular Net Income Over Time
| IMDX Stock | 7.32 0.63 9.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Insight Molecular Performance and Insight Molecular Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insight Molecular. Market participants price Insight higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Insight Molecular assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (3.79) | Revenue Per Share | Quarterly Revenue Growth 11.148 | Return On Assets | Return On Equity |
Understanding Insight Molecular requires distinguishing between market price and book value, where the latter reflects Insight's accounting equity. The concept of intrinsic value - what Insight Molecular's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Insight Molecular's price substantially above or below its fundamental value.
Please note, there is a significant difference between Insight Molecular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insight Molecular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Insight Molecular's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Insight Molecular and related stocks such as C4 Therapeutics, Sangamo Therapeutics, and Cybin Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCCC | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (34.1 M) | (66.3 M) | (83.9 M) | (128.2 M) | (132.5 M) | (105.3 M) | (94.8 M) | (99.5 M) |
| SGMO | (308 K) | (35.8 M) | (22.3 M) | (26.6 M) | (26.4 M) | (40.7 M) | (71.7 M) | (54.6 M) | (68.3 M) | (75.8 M) | (121.1 M) | (178.3 M) | (192.3 M) | (257.8 M) | (97.9 M) | (88.1 M) | (83.7 M) |
| OABI | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (17.6 M) | (27 M) | (22.3 M) | (50.6 M) | (62 M) | (55.8 M) | (53 M) |
| PRLD | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (27.6 M) | (56.9 M) | (110.8 M) | (107.3 M) | (121.8 M) | (127.2 M) | (114.5 M) | (120.2 M) |
| CDXS | (18.7 M) | (16.6 M) | (30.9 M) | (41.3 M) | (19.1 M) | (7.6 M) | (8.6 M) | (23 M) | (10.9 M) | (11.9 M) | (24 M) | (21.3 M) | (33.6 M) | (76.2 M) | (65.3 M) | (58.7 M) | (55.8 M) |
| ARMP | (5.1 M) | (3.8 M) | (1.1 M) | (64.6 M) | 23.1 M | (516 K) | (18.8 M) | (12.8 M) | (12.1 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (18.9 M) | (17 M) | (17.9 M) |
| IVVD | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (226.8 M) | (241.3 M) | (198.6 M) | (169.9 M) | (152.9 M) | (160.6 M) |
| PEPG | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (76.9 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
Insight Molecular and related stocks such as C4 Therapeutics, Sangamo Therapeutics, and Cybin Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Insight Molecular financial statement analysis. It represents the amount of money remaining after all of Insight Molecular Diagnostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Insight Molecular Diagnostics | IMDX |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 2 International Plaza |
| Exchange | NASDAQ Exchange |
null 7.32
Additional Tools for Insight Stock Analysis
When running Insight Molecular's price analysis, check to measure Insight Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insight Molecular is operating at the current time. Most of Insight Molecular's value examination focuses on studying past and present price action to predict the probability of Insight Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insight Molecular's price. Additionally, you may evaluate how the addition of Insight Molecular to your portfolios can decrease your overall portfolio volatility.